Mitochondrial Respiratory Function in Mammalian Skeletal Muscle

Cancer Clinical Trial

Official title:

Mitochondrial Respiratory Function in Mammalian Skeletal Muscle: Metabolic Insights Into Cancer and Burn Cachexia Through Comparative Physiology of Humans and Marine Mammals

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02650570
• Other study ID #: 15-0056
• Status: Terminated
• Phase: N/A
• First received: December 8, 2015
• Last updated: October 24, 2017
• Start date: February 14, 2017
• Est. completion date: March 29, 2017

Study information

• Verified date: October 2017
• Source: The University of Texas Medical Branch, Galveston
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether skeletal muscle mitochondrial function is altered in patients with head and neck cancer compared to healthy controls.

Description:

20 men and women, 30-60 years, equally divided between patients diagnosed with advanced (stages III or IV), persistent (recurrence within 6 months) or recurrent head and neck squamous cell carcinoma (HNSCC) (n=10) and healthy age matched control subjects (n=10) will be studied.

Muscle biopsies will be collected from cancer patients before and after a 4 week standard of care (SOC) treatment. Muscle biopsies from healthy control subjects will be collected at baseline only.

Lean body mass and fat mass will be determined by a DEXA scan before and after 4 week SOC treatment (cancer patients) to document any change in body composition (cachexia), and at baseline only in the age-matched healthy controls.

Blood will be collected from both cancer patients and healthy subjects to examine hormone levels at the time of biopsy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: March 29, 2017
• Est. primary completion date: March 29, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Men and women, aged 30-60 years.

2. Diagnosed with advanced (stages III or IV), persistent (recurrence within 6 months) or recurrent head and neck squamous cell carcinoma (HNSCC) and being treated at UTMB (n=10).

3. Healthy sex and age matched controls (n=10.)

4. Able to comprehend risks and sign a consent form.

5. Fluent in English

Exclusion Criteria:

1. Significant renal or heart disease or any acute metabolic disease.

2. Evidence of hepatitis as indicated by a 3-fold increase in of 2 out of 3 liver enzymes.

3. Diabetes mellitus or other untreated endocrine disease.

4. Recent (within 3 months) treatment with anabolic steroids.

5. Ongoing anticoagulant therapy.

6. Polycystic ovary syndrome (PCOS) and/or hyperthecosis.

7. Non-classical adrenal hyperplasia.

8. Cushing's syndrome.

9. Pregnancy.

10. Hyperprolactinoma, hypothyroidism.

11. Granulocyte Count below 1.5x103/µL

12. Platelet Count below 150 x 103/µL

13. White Blood Cell Count below 1.0x103/µL

14. Hemoglobin below 8.0 g/dL

15. Organ transplant, HIV, or other criteria deemed immunosuppressing by the PI or study physician.

16. Any other circumstance deemed exclusionary by the PI or study physician.

Related Conditions & MeSH terms

• Cachexia
• Cancer

Locations

Country	Name	City	State
United States	The University of Texas Medical Branch	Galveston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Medical Branch, Galveston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Baseline skeletal muscle oxygen consumption (pmol O2/s*mg) in head and neck cancer patients and healthy age-matched controls	Aerobic respiration will be measured from skeletal muscle biopsies of the vastus lateralis using Oroboros O2K high resolution respirometry. The average maximal skeletal muscle oxygen consumption of 10 head and neck cancer subjects will be compared to the average of 10 healthy controls.	Baseline
Primary	Skeletal muscle oxygen consumption (pmol O2/s*mg) in head and neck cancer patients following 4 weeks of standard of care.	Aerobic respiration will be measured from skeletal muscle biopsies of the vastus lateralis using Oroboros O2K high resolution respirometry. The average maximal skeletal muscle oxygen consumption of 10 head and neck cancer subjects after 4 weeks of standard of care (including chemotherapy, corticosteroids, etc. as prescribed by physician) will be compared to the average of their baseline measures.	4 weeks